Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension

Kathryn N. Farrow, Robin H Steinhorn

Research output: Chapter in Book/Report/Conference proceedingChapter

21 Scopus citations

Abstract

Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages251-277
Number of pages27
Volume204
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume204
ISSN (Print)01712004
ISSN (Electronic)18650325

Keywords

  • Bronchopulmonary dysplasia
  • cAMP
  • cGMP
  • Congenital diaphragmatic hernia
  • Nitric oxide
  • Persistent pulmonary hypertension of the newborn
  • Phosphodiesterase
  • Prostacyclin

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Fingerprint Dive into the research topics of 'Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension'. Together they form a unique fingerprint.

Cite this